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Latin America (LA)Background: Real-world data from different regions are needed to support the external validity of con-
trolled trials and assess the impact of new oral anticoagulants (NOAC) in clinical practice.
Methods: ‘‘GLORIA-AF” is a large, ongoing, multicenter, global, prospective registry program in patients
with newly diagnosed non-valvular atrial fibrillation (NVAF) at risk of stroke. Newly diagnosed patients
with NVAF (within 4.5 months) and a CHA2DS2-VASc score  1 were consecutively enrolled. The study
objective was to estimate the incidence rate of stroke and major bleeding after a two year follow up of
patients on dabigatran that participated in the ‘‘GLORIA-AF” study (Phase II) in Latin America.
Results: Latin America included 378 eligible patients that received dabigatran in eight countries
(Argentina, Brazil, Chile, Colombia, Ecuador, Mexico, Perú, and Venezuela): 56.3% were male; mean age
was 70.3 ± 10.8 years; 43.4% had paroxysmal AF; 36.0% persistent AF and 20.6% permanent AF. Mean
CHA2DS2-VASc score was 3.2 ± 1.4; mean HAS-BLED score was 1.2 ± 0.8. Incidence rates for clinical events
after 2-years of follow-up per 100 patient-years were as follows: stroke 0.33 (95% CI: 0.04–1.17), major
bleeding 0.49 (95% CI: 0.10–1.42) and all-cause death 4.06 (95% CI: 2.63–6.00). Persistence with dabiga-
tran at 6, 12 and 24 months was 91%, 86%, and 80%, respectively.
Conclusion: These regional data shows the sustained safety and effectiveness of dabigatran over two
years of follow-up, consistent with already available evidence. An increase in accessibility and incorpo-
ration of NOAC to anticoagulant treatment strategies could potentially have a positive impact on AF
stroke prevention in Latin America.
 2020 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Atrial fibrillation (AF) is the most common cardiac arrhythmia
with a lifetime risk for development of 1 in 4 for the population
with 40 years of age and older [1].Data from local databases and their respective national health-
care systems in seven Latin American (LA) countries showed a
range of prevalence from 1.4% to 2.0% for AF in the general popu-
lation over 40 years old, with non-valvular AF (NVAF) accounting
for over 85% of cases [2]. Prevalence increases with age, ranging
from 2.2% to 2.3% in people aged 60 to 69 years to 8.2% to 8.5%
in those aged  80 years [2].
Vitamin K antagonists (VKA) have been the standard of care for
stroke prevention in AF, with reductions in stroke by 64% and mor-
tality by 26% [3]. Despite the evidence showing its efficacy, antico-
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the country, 18.3% to 24.6% of the AF population [2], and up to
51.2% of the patients with CHADS2 score  2 (Realise AF study),
received no VKA treatment [4]. Moreover, underuse tends to
increase with age [2,5]. Also, a study in Argentina that evaluated
consecutive patients with ischemic stroke and prior diagnosis of a-
trial fibrillation showed that only 54% of patients receiving VKA
had an international normalized ratio (INR) within therapeutic
ranges [6]. VKA has several drawbacks, such as slow onset of
action, variable dose–response, and significant food and drug inter-
actions with frequent monitoring requirements.
Non-VKA oral anticoagulants (NOAC) are changing the current
management of AF stroke prevention. Current guidelines recom-
mend NOAC over warfarin in patients eligible to NOAC therapy,
including all patients except those with moderate-to-severe mitral
stenosis or a mechanical heart valve [7,8].
Dabigatran was the first NOAC approved by the FDA in 2010
based on the results of phase III RE-LY study that included patients
who had NVAF at risk of stroke. In RE-LY, dabigatran 150 mg twice
daily was superior to warfarin for preventing all stroke/systemic
embolism and ischemic stroke, with rates of major bleeding similar
to warfarin. The dabigatran 110 mg twice-daily dose was non-
inferior to warfarin for preventing stroke/systemic embolism, with
considerably less major bleeding [9,10]. Both dosages of dabigatran
were associated with significantly lower rates of intracranial hem-
orrhage (ICH) compared to warfarin [10].
Additional regional data are needed to support the external
validity of randomized controlled trials (RCT) and to better under-
stand the use of newly approved drugs outside the context of RCT.
The GLORIA-AF Registry was designed to provide additional
information in different regions on patients with recent-onset
NVAF at risk of stroke with a special focus on effectiveness and
safety of dabigatran [11]. Herein we report the analysis of the LA
patients included in Phase II of the GLORIA AF that were treated
with dabigatran.
2. Methods
2.1. Design and study population
The design and rationale of the three phased GLORIA-AF global
non-interventional registry has been previously published [11].
GLORIA-AF included consecutive adult patients with newly
diagnosed NVAF (within the last 4.5 months) at risk of stroke with
a CHA2DS2-VASc score  1. Patients with mechanical valves, prior
VKA therapy for > 60 days, other medical indications for chronic
VKA therapy, AF due to a reversible cause, and life
expectancy < 1 year were excluded. The HAS-BLED bleeding score
assessed bleeding risk. Centers were selected to reflect those that
typically manage new AF in LA.
Phase II of this global registry started when dabigatran was
approved in each of the participating countries with the collection
of data on the baseline characteristics (including demographics,
comorbid disease, and characteristics of AF). In patients prescribed
dabigatran, a two year follow up was performed to assess effective-
ness and safety. Follow up visits after baseline assessment took
place at 3, 6, 12 and 24 months. Dabigatran was prescribed accord-
ing to the local approved label and judgment of the treating physi-
cian (150 and 110 mg twice daily-BID). One patient that received
75 mg BID was excluded from the study population eligible for
analysis.
Data were collected from medical records obtained in clinical
practice setting and was recorded in a specifically designed web-
based electronic data collection form to ensure confidentiality,
completeness, and integrity. Additional quality measures included
automatic, manual and independent data checks.2
2.2. Study outcomes
Two-year effectiveness outcomes included stroke (ischemic or
hemorrhagic or unknown type/uncertain classification stroke),
and the composite outcome of stroke, systemic embolism, myocar-
dial infarction, life-threatening bleed, and vascular death. Addi-
tional outcomes analyzed were myocardial infarction (MI),
vascular death, and all-cause death (including vascular, non-
vascular and death of unknown cause). Safety outcome was major
bleeding defined as reduction in hemoglobin level of  2 g/L or
transfusion of  2 units (U) of blood or symptomatic bleeding in
a critical area or organ. Persistence was analyzed through the pro-
portion of patients discontinuing dabigatran (suspension of treat-
ment longer than 30 days or switch to another OAC) at 6, 12 and
24 months.
2.3. Ethics
The study was approved by local applicable ethics committees
and conducted according to good pharmacoepidemiology practice
guidelines and local country regulations for observational clinical
research. All patients signed a written informed consent before
entering the study.
2.4. Statistical analysis
Descriptive results are presented with data summarized by
means and standard deviations for continuous variables and by fre-
quencies and percentages for categorical variables. Crude incidence
rates are shown per 100 patient-years with two-sided 95%
confidence intervals (CI) based on the Poisson distribution and its
relation to Chi-square distribution and are based on the period of
index dabigatran exposure (on-treatment analysis). This period
is from the commencement of dabigatran until permanent discon-
tinuation (that is treatment stop > 30 days, switch to another
treatment, or study completion/discontinuation). Treatment
interruptions < 30 days were disregarded for the outcome analysis
and these patients were considered to be on continuous treatment.
Only events occurring while the patient was on the first treatment
regimen was considered, in case of recurrent events for one
patient, only the first event was considered. The probability of
treatment persistence was estimated from Kaplan Meier curve
analysis. No statistical hypothesis tests were performed. Statistical
analysis was performed using SAS software version 9.4 (SAS Insti-
tute Inc., Cary, NC, USA).3. Results
From November 2011 to December 2014, a total of 15,644
patients were globally enrolled in phase II at 984 centers across
44 countries. Of these, 4964 were prescribed dabigatran, of whom
4873 were eligible for analysis. Among them 378 (7.8%) were from
eight LA countries (Argentina, Brazil, Chile, Colombia, Ecuador,
Mexico, Peru, and Venezuela). They received dabigatran (150 mg
or 110 mg twice a day) and were eligible for analysis, see Fig. 1.
3.1. Patient population
For the LA population, the mean age at enrollment was 70.3 ± 1
0.8 years, and 56.3% were male. Paroxysmal AF was present in
43.4% of the patients, 36.0% had persistent AF, and 20.6% had per-
manent AF. The most prevalent comorbidity was history of hyper-
tension in 77.5% of the patients followed by congestive heart
failure in 31.2% and diabetes in 20.1%. Coronary artery disease
was present in 11.6% of the patients, 8.5% had prior myocardial
Fig. 1. GLORIA AF, Phase 2 Flow Chart.
Table 1
Eligible patients in Phase 2 from Latin America. Baseline characteristics by dabigatran
dose group.
Total
Population
Dabigatran
150 mg BID
Dabigatran
110 mg BID
Patients, n* 378 202 176
Age, mean (SD), years 70.3 (10.8) 66.0 (11.0) 75.2 (8.3)
BMI, mean (SD), kg/m2 28.36 (5.01) 29.44 (4.85) 27.11 (4.92)
Sex, male, n (%) 213 (56.3) 122 (60.4) 91 (51.7)
Type of AF, n (%)
Paroxysmal 164 (43.4) 83 (41.1) 81 (46.0)
Persistent 136 (36.0) 82 (40.6) 54 (30.7)
Permanent 78 (20.6) 37 (18.3) 41 (23.3)
Categorization of AF, n
(%)
Symptomatic 113 (29.9) 67 (33.2) 46 (26.1)
Minimally symptomatic 143 (37.8) 82 (40.6) 61 (34.7)
Asymptomatic 122 (32.3) 53 (26.2) 69 (39.2)
Medical history, n (%)
Previous stroke 31 (8.2) 17 (8.4) 14 (8.0)
MI 32 (8.5) 17 (8.4) 15 (8.5)
Coronary artery disease 44 (11.6) 21 (10.4) 23 (13.1)
Congestive heart failure 118 (31.2) 59 (29.2) 59 (33.5)
History of hypertension 293 (77.5) 164 (81.2) 129 (73.3)
Diabetes mellitus 76 (20.1) 47 (23.3) 29 (16.5)
Prior bleeding 20 (5.3) 6 (3.0) 14 (8.0)
Creatinine clearance,
mean (SD), mL/min
76.7 (31.6) 88.1 (32.4) 62.5 (23.8)
CHA2DS2-VASc, mean
(SD)
3.2 (1.4) 2.9 (1.5) 3.6 (1.3)
HAS-BLED score, mean
(SD)
1.2 (0.8) 1.0 (0.9) 1.4 (0.7)
Medications, n (%)
Antiplatelet* 77 (20.4) 44 (21.8) 33 (18.8)
Other cardiovascular** 351 (92.9) 190 (94.1) 161 (91.5)
PPI 81 (21.4) 50 (24.8) 31 (17.6)
Acronyms: AF, atrial fibrillation; BID, twice a day; BMI, body mass index; MI,
myocardial infarction; PPI, proton pump inhibitor; SD, standard deviation.
* Antiplatelet use on the baseline visit date.
** Antihypertensive/heart failure and antiarrhythmic therapy.
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3.2 ± 1.4 and mean HAS-BLED score was 1.2 ± 0.8. The mean crea-
tinine clearance was 76.7 ± 31.6 ml/min and history of prior bleed-
ing was reported in 5.3% of LA patients. Table 1 shows the baseline
characteristics of the LA population.
3.2. Dabigatran treatment
For the LA population, the prescribed dose of dabigatran was
150 mg BID in 53.4% of the patients, 110 mg BID in 46.6%, (Table 1).
Antiplatelet treatment was used together with dabigatran in 20.4%
of the patients, mostly aspirin (18.3% of patients), see Table 1.
Dabigatran was prescribed by cardiologists (90.7%), other treating
physicians included general practitioners (5.6%) and internists
(3.7%). Patients taking low doses of dabigatran (110 mg BID) were
older, with lower creatinine clearances, higher CHA2DS2-VASc, and
HAS-BLED scores, and more often with prior bleeding, see Table 1.
A total of 47 patients with creatinine clearances<50 ml/min were
included. Of these patients 72.3% received 110 mg BID, and 27.7%
150 mg BID.
3.3. Effectiveness and safety outcomes
Incidence rate for stroke after 2-years of follow up was 0.33
(95% CI: 0.04–1.17) per 100 patient-years. Incidence rate for
myocardial infarction was 0.98 (95% CI: 0.36–2.13) per 100
patient-years. The incidence rate for major bleeding was 0.49
(95% CI: 0.10–1.42) per 100 patient-years. The incidence rate for
all-cause death was 4.06 (95% CI: 2.63–6.00). The incidence rate
for the composite outcome of SSE, myocardial infarction, life-
threatening bleeding, and vascular death was 2.45 (95% CI: 1.37–
4.03) per 100 patient-years. (Table 2).
3.4. Dabigatran persistence
The probability of treatment persistence (estimated from
Kaplan Meier curves) with dabigatran at 6 months was 90.6%3
(95% CI: 87.1%-93.1%), at 12 months it was 85.7% (95% CI: 81.6%-
88.9%) and at 24 months it was 80.2% (95% CI: 75.7%-84.0%).4. Discussion
The current global landscape of AF stroke prevention has chan-
ged since NOAC regulatory approval [12]. GLORIA-AF is a prospec-
tive global real-world data registry providing long term follow-up
data of patients with newly diagnosed NVAF treated with dabiga-
tran. Even though the burden of AF is high in LA, with up to
51.2% of patients at high risk of stroke not receiving adequate
antithrombotic therapy, there is limited information on modern
AF antithrombotic management and outcomes in this region [4].
Exploring similarities and differences in efficacy and safety across
regions in the controlled trial and real-world setting is of great
importance for healthcare management.
In the LA patients in GLORIA-AF, the overall incidence of stroke
for dabigatran treated patients was 0.33 (95% CI: 0.04–1.17) per
100 patient-years after two years of follow up. These low numbers
are consistent and even lower in comparison to the main results at
the global level for the registry, where the rate of stroke was 0.65
(95% CI: 048–0.87) [13,14].
The LA subset of RE-LY compared to the patients in the current
study was characterized by having a greater percent of permanent
AF (70.7% vs. 20.6%) and comorbidities such as hypertension (82.3%
vs. 77.5%), congestive heart failure (41.1% vs 31.2%) and prior
stroke (11.5% vs. 8.2%) with a higher mean CHA2DS2-VASc score
(3.5 vs 3.2) and aspirin use (48.8% vs. 18.3%).
Table 2
Effectiveness and safety outcomes in treated patients from Latin America. Crude
incidence rates.
Latin America (n = 376)
Patients
with
event
Patient
years
Crude IR
per 100
PY (95%
CI)
Stroke 2 615 0.33
(0.04–
1.17)
-Ischemic stroke 1
-Unknown type/uncertain
classification
1
Major bleeding 3 615 0.49
(0.10–
1.42)
-Life-threatening 2
-Transfusion (2 + units of blood/red
cells)
2
-Fall in haemoglobin of 2 g/dL 2
-Fatal bleeds 2
-Gastrointestinal 3
-Intracranial 0
Myocardial Infarction 6 614 0.98
(0.36–
2.13)
All-cause death 25 615 4.06
(2.63–
6.00)
-Vascular death 8
-Nonvascular death 11
-Unknown 6
Composite outcome (Stroke, systemic
embolism, myocardial infarction,
life-threatening bleed, vascular
death)
15 613 2.45
(1.37–
4.03)
Acronyms: CI-Confidence interval; IR-Incidence rate; PY-Patient-years.
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pared with the LA specific dabigatran patients was characterized
by a higher prevalence of prior stroke (11.9% vs. 8.2%) and a history
of diabetes (22.7% vs. 20.1%), however the mean CHA2DS2-VASc
score of 3.2 was the same [13].
The observed differences in baseline clinical characteristics
with a lower risk population in our study may explain the lower
rates of stroke and bleeding complications that we observed in this
study.
Evidence from RE-LY and meta-analysis of studies on NOAC
indicate that the effectiveness of NOAC for prevention of SSE may
differ between geographic regions similar to differences in stroke
rates observed with warfarin [15,16]. Less effective management
of care with VKA therapy in Asia and LA patients may explain
the greatest benefit observed with NOAC therapy in these regions
[15,16].
In the eligible LA patients in GLORIA-AF, the overall incidence of
major bleeding for dabigatran patients was 0.49 (95% CI: 0.10–
1.42) per 100 patient-years after two years of follow up. Compara-
tive risks of major bleeding among newly diagnosed NVAF patients
who initiate VKA or NOAC in real-world clinical practice have been
recently published [17–19]. In a Danish registry that included pa-
tients with NVAF who were naive to oral anticoagulants, annual
rates of any bleeding for dabigatran (2.4%) were significantly lower
than for warfarin (5.0%) (HR 0.62, 95%CI: 0.51 to 0.74), [17]. In a
Norwegian registry that included NVAF patients with the first pre-
scription of oral anticoagulants, use of dabigatran (HR 0.74, 95% CI
0.66–0.84, P < 0.001) was associated with a lower risk of major or
clinically relevant non-major bleeding compared with warfarin4
[18]. A US-based study used propensity score matching to balance
age, sex, region, baseline comorbidities, and co-medications. Com-
pared to matched warfarin initiators, dabigatran (HR: 0.69; 95% CI:
0.50–0.96) initiators had a significantly lower risk of major bleed-
ing [19]. These data are supported by other population-based
propensity cohort studies including NOAC, and well-managed
VKA matched cohort, showing lower bleeding risk with NOACs
[20,21].
Our study showed a very high treatment persistence with dabi-
gatran in LA patients at 12 and 24 months, which was 85.7% and
80.2%, respectively. In the Phase II of GLORIA-AF, the probability
of dabigatran treatment persistence was 76.6% at 12 months and
69.2% at 24 months [22]. In the global GLORIA-AF registry, patients
in the LA region were at lower risk for non-persistence (HR 0.61;
95% CI: 0.40 to 0.90), and patients with asymptomatic or minimally
symptomatic AF, permanent AF and those not on proton pump
inhibitors were more likely to be persistent [22]. The observed dif-
ferences in persistence with a higher rate in our patients compared
with the overall dabigatran patients in Phase II of GLORIA may
explain the lower rates of stroke that we observed in this study.
Persistence is of great relevance as treatment discontinuation with
VKAs is high with only 45–53.5% of patients remaining on treat-
ment after one year [23,24].
A US-based study in newly diagnosed patients with NVAF
naive-to-treatment, identified by propensity score matching 1775
pairs of patients on dabigatran and warfarin . The persistence rates
were higher for dabigatran than for warfarin at both six months
(72% versus 53%) and one year (63% versus 39%). Patients on dabi-
gatran with a low-to-moderate risk of stroke (CHADS2 score < 2) or
with a higher bleed risk (HEMORR2HAGES > 3) had a higher likeli-
hood of non-persistence (hazard ratios, 1.37; 95% CI, 1.17–1.60;
P < 0.001; and hazard ratios, 1.24; 95% CI, 1.04–1.47; P = 0.016)
respectively, [25].
Importantly, in our study, dabigatran was prescribed and man-
aged mostly by cardiologists, which is in contrast with usual man-
agement of VKA in anticoagulation clinics in most LA countries,
similar to what is seen in countries like The Netherlands, England
and Spain [26]. This additional factor needs to be further investi-
gated as a potential contributor to widespread treatment and
adherence to stroke prevention therapy in NVAF in our region.
4.1. Limitations
Our study has limitations related to the observational design
and, therefore, subject to potential selection bias and unmeasured
confounding. The small size of LA patient subset within the global
GLORA-AF registry is a second limitation that may limit the gener-
alizability of results.
In conclusion, the effectiveness and safety results, consistency
with final Phase II of GLORIA-AF, and other real-world registries
provide evidence of the benefit and safety of dabigatran in stan-
dard clinical practice in our region. The epidemiological burden
of AF in LA and the suboptimal treatment with VKAs leads to great
room for improvement in the prevention of stroke and SE among
LA population. An increase in accessibility and incorporation of
NOAC to treatment strategy may have a positive health impact
on AF stroke prevention in the LA region.
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